Updates to Clinical Information on Anticancer Immunotherapy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: Over the last several years, immunotherapy has become one of the most promising therapeutic options for cancer. This study aims to summarize the updates on cancer immunotherapy focusing on immune checkpoint inhibitors, such as programmed cell death-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors, which have received attention as new anticancer therapeutic agents. Methods: A literature survey was carried out on PubMed to identify high-impact papers on cancer immunotherapy from 2010. The most recent data on clinical efficacy and safety have been included highlighting the response characteristics to recently approved immunotherapeutic agents. Results: In various cancers, immune checkpoints are a means for cancer cells to evade the immune system. Furthermore, CTLA-4 and PD-L1 can be overexpressed, allowing malignant cells to evade T-cells. Numerous clinical trials have been performed to seek appropriate indication of these products in various cancer types. Among them, the most conspicuous types are melanoma, non-small-cell lung cancer, and head and neck cancer. The approval of ipilimumab by Food and Drug Administration (FDA) commenced a new era of cancer immunotherapy. This was followed by the approval of nivolumab and pembrolizumab. Currently, combination therapies are being investigated for various cancer types. Conclusion: In this study, we reviewed recently reported scientific and clinical evidence for currently approved immune checkpoint inhibitors. Although these novel checkpoint inhibitors are ever evolving for cancer therapies, there exist limitations that need to be overcome, indicating the necessity for further studies aiming to improve their efficacy, toxicity, and cost.
Abstract
Objective: Over the last several years, immunotherapy has become one of the most promising therapeutic options for cancer. This study aims to summarize the updates on cancer immunotherapy focusing on immune checkpoint inhibitors, such as programmed cell death-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors, which have received attention as new anticancer therapeutic agents. Methods: A literature survey was carried out on PubMed to identify high-impact papers on cancer immunotherapy from 2010. The most recent data on clinical efficacy and safety have been included highlighting the response characteristics to recently approved immunotherapeutic agents. Results: In various cancers, immune checkpoints are a means for cancer cells to evade the immune system. Furthermore, CTLA-4 and PD-L1 can be overexpressed, allowing malignant cells to evade T-cells. Numerous clinical trials have been performed to seek appropriate indication of these products in various cancer types. Among them, the most conspicuous types are melanoma, non-small-cell lung cancer, and head and neck cancer. The approval of ipilimumab by Food and Drug Administration (FDA) commenced a new era of cancer immunotherapy. This was followed by the approval of nivolumab and pembrolizumab. Currently, combination therapies are being investigated for various cancer types. Conclusion: In this study, we reviewed recently reported scientific and clinical evidence for currently approved immune checkpoint inhibitors. Although these novel checkpoint inhibitors are ever evolving for cancer therapies, there exist limitations that need to be overcome, indicating the necessity for further studies aiming to improve their efficacy, toxicity, and cost.
참고문헌 (37)
- Wolchok J.D, "The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation", The Oncologist, 13(Supplement 4), pp.2~9 (2008)[DOI]
- Buchbinder E. I, "CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of their Inhibition", Am J ClinOncol, 39, pp.98~106 (2016)
- Bardhan K, "The PD1:PD-L1", 2 Pathway from Discovery to Clinical Implementation, 2016, pp.7(550), 1~17
- Shi L, "The Role of PD-1and PD-L1 in T-cell Immune Suppression in Hematological Malignancies", J Hematol Oncol, 6, pp.74~80 (2013)
- Hodi F.S, "Improved Survival with Ipilimumb in Patients with Metastatic Melanoma", N Engl J Med, 363, pp.711~723 (2010)[DOI]
- Graziani G, "Ipilimumab: A Novel Immunostimulatory Monoclonal Antibody for the Treatment of Cancer", Pharmacol Res, 65, pp.9~22 (2012)[DOI]
- Larkin J, "Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma", N Engl J Med, 373, pp.23~34 (2015)[DOI]
- Hellmann M.D, "Nivolumab plus ipilimumab as First-line Treatment for Advanced Non-Small-Cell Lung Cancer(CheckMate 012):Results of an Open-Label, Phase 1, Multicohort Study", Lancet Oncol, 18, pp.31~41 (2017)
- Robert C, "Nivolumab in Previously Untreated Melanoma without BRAF Mutation", N Engl J Med, 372, pp.320~330 (2015)[DOI]
- Ribas A, "Pemtrolizumab versus Investigator-Choice Chemotherapy for Ipilimumab-Refractory Melanoma (KEYNOTE-002): a randomized, controlled, phase 2 trial", THE LANCET oncology, 16, pp.908~918 (2015)[DOI]
- Robert C, "Pembrolizumab versus Ipilimumab in Advanced Melanoma", N Engl J Med, 372, pp.2521~2532 (2015)
- Rosenberg J.E, "Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma who have Progressed Following Treatment with Platinum-Based Chemotherapy: A Single Arm, phase 2 trial", Lancet, 387, pp.1909~1920 (2016)
- Kaufman H, "Avelumab in Patients with Chemotherapy-Refractory Metastatic Merkel Cell Carcinoma: A Multicenter, Single-Group, Open-Label, Phase 2 Trial", Lancet Oncol, 17, pp.1374~1385 (2016)
- Massard C, "Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer", J ClinOncol, 34, pp.3119~3126 (2016)[DOI]
- Bellmunt J, "J, A Review on the Evolution of PD-1", PD-L1 immunotherapy for Bladder Cancer: The Future is Now, 2017, pp.54, 58~67
- Topalian S.L, "Mechanism-Driven Biomarkers to Guide Immune Checkpoint Blockade in Cancer Therapy", Nat Rev Cancer, 16, pp.275~287 (2016)[DOI]
- Topalian S.L, "Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer", N Engl J Med, 366, pp.2443~2454 (2012)[DOI]
- Teixido C, "Predictive Factors for Immunotherapy in Melanoma", Ann Transl Med, 3, pp.208~ (2015)
- Taube J.M, "Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy", Clin Cancer Res, 20, pp.5064~5074 (2014)[DOI]
- Messina J, "12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy", Sci Rep, 2, pp.765~771 (2012)[DOI]
- Zaretsky J.M, "Mutations Associated with Acquired Resistance to PD-1 Blocked in Melanoma", N Engl J Med, 375, pp.819~829 (2016)[DOI]
- Snyder A, "Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma", N Engl J Med, 371, pp.2189~2199 (2014)
- Heppt M.V, "The Systemic Management of Advanced Melanoma in 2016", Oncol Res Treat, 39, pp.635~642 (2016)
- Gibney G.T, "Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy", Lancet Oncol, 16, pp.e542~e551 (2016)
- Pennock G.K, "The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment", The Oncologist, 20, pp.812~822 (2015)[DOI]
- Ansell S.M, "PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma", N Engl J Med, 372, pp.311~319 (2015)[DOI]
- Weber J.S, "Nivolumab Versus Chemotherapy in Patients with Advanced Melanoma who Progressed after Anti-CTLA-4 Treatment (CheckMate 037): A Randomized, Controlled, Open-Label, Phase 3 Trial", Lancet Oncol, 16, pp.375~384 (2015)[DOI]
- Sadraei N. H, "Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer", Am Soc Clin Oncol Educ Book, 35, pp.e277~e281 (2016)
- Rozali E.N, "Programmed Death Ligand 2 in Cancer-Induced Immune Suppression", Clinical and Developmental Immunology, pp.1~8 (2012)
- Rizvi N.A, "Activity and Safety of Nivolumab, an Anti-PD-1 Immune Checkpoint inhibitor, for Patients with Advanced, Refractory Squamous Non-Small-Cell Lung Cancer (CheckMate 063): A Phase 2, Single-Arm Ttrial", Lancet Oncol, 16, pp.257~265 (2015)
- Apolo A.B, "Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study", J Clin Oncol, 35, pp.2117~2126 (2016)
- LiY, "A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1", PD-L1 Pathway &Translational Blockade of Immune Checkpoints, 2016, pp.17, 1151~1173
- Yu H, "PD-L1 Expression in Lung Cancer", J Thorac Oncol, 11, pp.964~975 (2016)
- Garon E.B, "Pembrolizumab for the Treatmentof Non-Small-Cell Lung Cancer", N Engl J Med, 372, pp.2018~2028 (2015)[DOI]
- Nghiem P.T, "PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma", N Engl J Med, 374, pp.2542~2552 (2016)[DOI]
- Mozzillo N., "Melanoma: the Role of Surgery in the Era of New Therapies", J Transl Med, 12, pp.195~ (2014)[DOI]
- Patel M.R, "Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Metastatic Urothelial Carcinoma Progressed after Platinum-Based Therapy or Platinum Ineligible", Ann Oncol, 27(Supplement 6), pp.vi266~vi295 (2016)